The focus of our clinical research is essentially on respiratory research, in particular on allergic rhinitis, asthma, COPD, and idiopathic pulmonary fibrosis (IPF).
Over the past five years, we have moved into other therapeutic areas as well, such as atopic dermatitis, inflammatory diseases, and also vaccine studies. We combine our scientific expertise with operational excellence in clinical trials.
Exhaled particles are very small and provide a fingerprint of the epithelial lining fluid. We have developed a technique by which we can determine the deposition of exhaled particles with every single breath.
Exhaled particles are an intriguing method with broad potential for non-invasive monitoring of the lung.
The life expectancy of patients with untreated idiopathic pulmonary fibrosis (IPF) is three years.
We are focusing on translational and clinical research and have unique access to primary cells derived from patients with IPF or other types of pulmonary fibrosis. We test medical compounds and their effect on epithelial cell biology using our specialized in-vivo and in-vitro models.
Read more about clinical and translational research on pulmonary fibrosis at Fraunhofer ITEM
Specific and validated biomarkers are a key tool for us in routine clinical practice and clinical studies to allow detection of diseases at an early stage and their individualized treatment, to enable prognoses and monitoring of the response to therapy.
To clients and partners, we guarantee the highest quality standards – GLP/GCLP –, individual method development and state-of-the-art technologies.
Chip cytometry is based on the immobilization of cells on special object slides, referred to as chips. On these chips, cells can be analyzed with regard to morphology, expression of surface markers, and intracellular function.
Iterative staining protocols allow comprehensive immunological and functional characterization of cells.
The team of our Sputum Core Facility has comprehensive experience, enabling optimal sputum analysis results in multicenter clinical trials, due to central organization and analyses.
We guarantee selection of the most suitable sputum analysis protocol to optimally fit the requirements of your specific study. We offer our clients study-specific training, supervision of quality during study conduct, and analysis of a broad spectrum of biomarkers.
Fraunhofer Institute for Toxicology and Experimental Medicine